Tyra Biosciences Shares Drop 22% After Bladder Cancer Drug Fails Clinical Trial

Tyra Biosciences stock plummeted following disappointing results from a Phase 3 trial of its experimental bladder cancer treatment, raising concerns about the company's near-term pipeline prospects.

9 Sept, 14:44 — 9 Sept, 14:44

Post Share

Sources

Showing 1 of 1 sources

Barron'sHigh1h ago

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Barron's

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress Barron's

Read full article →

Tyra Biosciences Shares Drop 22% After Bladder Cancer Drug Fails Clinical Trial

Sources

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Barron's

Related Stories

Greek Pop Star Giorgos Mazonakis Dies of Cardiac Arrest at 54

Greek Woman Gives Birth Using Embryo Frozen for Over 22 Years

Over 1,000 Children Die in Bangladesh Measles Outbreak Linked to Vaccine Gaps

West Nile Virus Cases Confirmed in Moldova and Crete